Novo Nordisk to Buy Obesity Drug Developer Inversago Pharma for Nearly $1.1 Billion
- August 11, 2023
Novo Nordisk A/S, which manufacturers Wegovy, announced August 10 plans to add to its weight-loss drug portfolio by acquiring Canadian drug maker Inversago Pharma for up to 1.075 billion.
ARTICLE TAGS
You must be logged in to access this content.